Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan CASI Pharmaceuticals, Inc. (CASI)

The development of CASI Pharmaceuticals (CASI) relies on the introduction of oncology drugs to the Chinese market and regulatory approvals. This quarterly earnings per share growth chart visualizes these complexities, where the 0.00 mark serves as a key metric. Risks are linked to capital shortages and geopolitics, while business resilience is ensured by exclusive imports within the PRC's national subsidy system.

casipharmaceuticals.com (CASI) - Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan saka 04.07.2022 nganti 14.03.2026

CASI (CASI Pharmaceuticals): rincian analitis lan laporan miturut indikator

- nilai pasar lan prakiraan target analis:

Bagan rega casipharmaceuticals.com|CASI - Rata-rata rega prakiraan

- rincian kapitalisasi pasar:

Nilai pasar CASI|CASI - Total Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham CASI Pharmaceuticals|CASI - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku casipharmaceuticals.com|CASI - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal CASI Pharmaceuticals|CASI - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas casipharmaceuticals.com|CASI - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku CASI|CASI - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan CASI Pharmaceuticals|Likuiditas cepet casipharmaceuticals.com

- indikator bathi lan kelipatan valuasi:

CASI - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep CASI Pharmaceuticals|CASI - Nilai perusahaan marang bathi resik|Pangali Forward P/E casipharmaceuticals.com|CASI - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CASI|CASI - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan CASI Pharmaceuticals|CASI - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan casipharmaceuticals.com|CASI - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep CASI Pharmaceuticals

Analisis kabeh metrik perusahaan:CASI Pharmaceuticals Inc. - CASI

To filter out asset overvaluation risks, it is necessary to evaluate the dynamics of net earnings per share, calculated as the ratio of total income minus all expenses to the number of securities. By analyzing the quarterly earnings per share chart, an investor can determine how effectively the licensing of Western oncology drugs in China converts into real yield growth for CASI Pharmaceuticals (CASI).

Pesaing CASI Pharmaceuticals (CASI)